MYRBETRIQ

MYRBETRIQ® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with
symptoms of urge urinary incontinence, urgency, and urinary frequency.
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat
overactive bladder
ommon side effects include high blood pressure, headaches, and urinary tract infections.[2] Other
significant side effects include urinary retention, irregular heart rate, and angioedema.
Adverse effects by incidence:[1][8][9]
Very common (>10% incidence) adverse effects include:
 Elevated blood pressure
Common (1–10% incidence) adverse effects include:
 Dry mouth
 Nasopharyngitis
 Urinary tract infection (UTI)
 Headache
 Influenza
 Constipation
 Dizziness
 Joint pain
 Cystitis
 Back pain
 Upper respiratory tract infection (URTI)
 Sinusitis
 Diarrhea
 High heart rate
 Fatigue
 Abdominal pain
 Neoplasms (cancers)
Rare (<1% incidence) adverse effects include:
 Palpitations
 Blurred vision
 Glaucoma
 Indigestion
 Gastritis
 Abdominal distension
 Rhinitis
 Elevations in liver enzymes (GGTP, AST, ALT and LDH)
 Renal and urinary disorders (e.g., nephrolithiasis, bladder pain)
 Reproductive system disorders (e.g., vulvovaginal pruritus, vaginal infection)
 Skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash,
pruritus, purpura, lip edema)
 Stevens–Johnson syndrome associated with increased serum ALT, AST and bilirubin
 Urinary retention
Mechanism of action
Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in

vitro laboratory experiments using the cloned human beta-3 AR. Mirabegron relaxes the detrusor
smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of
beta-3 AR which increases bladder capacity. Although mirabegron showed very low intrinsic
activity for cloned human beta-1 AR and beta-2 AR, results in humans indicate that beta-1 AR
stimulation occurred at a mirabegron dose of 200 mg.
CONTRAINDICATIONS
MYRBETRIQ® is contraindicated in patients who have known hypersensitivity reactions to

mirabegron
Pharmacodynamics
Urodynamics
The effects of MYRBETRIQ® on maximum urinary flow rate and detrusor pressure at maximum
flow rate were assessed in a urodynamic study consisting of 200 male patients with lower urinary
tract symptoms (LUTS) and BOO. Administration of MYRBETRIQ® once daily for 12 weeks
did not adversely affect the mean maximum flow rate or mean detrusor pressure at maximum
flow rate in this study. Nonetheless, MYRBETRIQ® should be administered with caution to
patients with clinically significant BOO [see WARNINGS AND PRECAUTIONS].
Cardiac Electrophysiology
The effect of multiple doses of MYRBETRIQ® 50 mg, 100 mg and 200 mg once daily on QTc
interval was evaluated in a randomized, placebo-and active-controlled (moxifloxacin 400 mg)
four-treatment-arm parallel crossover study in 352 healthy subjects. In a study with demonstrated
ability to detect small effects, the upper bound of the one-sided 95% confidence interval for the
largest placebo adjusted, baseline-corrected QTc based on individual correction method (QTcI)
was below 10 msec. For the 50 mg MYRBETRIQ® dose group (the maximum approved dosage),
the mean difference from placebo on QTcI interval at 4-5 hours post-dose was 3.7 msec (upper
bound of the 95% CI 5.1 msec).
For the MYRBETRIQ® 100 mg and 200 mg doses groups (dosages greater than the maximum
approved dose and resulting in substantial multiples of the anticipated maximum blood levels at
50 mg), the mean differences from placebo in QTcI interval at 4-5 hours post-dose were 6.1
msec (upper bound of the 95% CI 7.6 msec) and 8.1 msec (upper bound of the 95% CI 9.8
msec), respectively. At the MYRBETRIQ® 200 mg dose, in females, the mean effect was 10.4
msec (upper bound of the 95% CI 13.4 msec).
In this thorough QT study, MYRBETRIQ® increased heart rate on ECG in a dose dependent
manner. Maximum mean increases from baseline in heart rate for the 50 mg, 100 mg, and 200
mg dose groups compared to placebo were 6.7 beats per minutes (bpm), 11 bpm, and 17 bpm,
respectively. In the clinical efficacy and safety studies, the change from baseline in mean pulse
rate for MYRBETRIQ® 50 mg was approximately 1 bpm. In this thorough QT study,
MYRBETRIQ® also increased blood pressure in a dose dependent manner (see Effects On
Blood Pressure).
Effects On Blood Pressure
In a study of 352 healthy subjects assessing the effect of multiple daily doses of 50 mg, 100 mg,
and 200 mg of MYRBETRIQ® for 10 days on the QTc interval, the maximum mean increase in
supine SBP/DBP at the maximum recommended dose of 50 mg was approximately 4.0/1.6 mm
Hg greater than placebo. The 24-hour average increases in SBP compared to placebo were 3.0,
5.5, and 9.7 mm Hg at MYRBETRIQ® doses of 50 mg, 100 mg and 200 mg, respectively.
Increases in DBP were also dose-dependent, but were smaller than SBP.
In another study in 96 healthy subjects to assess the impact of age on pharmacokinetics of

multiple daily doses of 50 mg, 100 mg, 200 mg, and 300 mg of MYRBETRIQ® for 10 days, SBP
also increased in a dose-dependent manner. The mean maximum increases in SBP were
approximately 2.5, 4.5, 5.5 and 6.5 mm Hg for MYRBETRIQ® exposures associated with doses
of 50 mg, 100 mg, 200 mg and 300 mg, respectively.
In three, 12-week, double-blind, placebo-controlled, safety and efficacy studies (Studies 1, 2 and
3) in OAB patients receiving MYRBETRIQ® 25 mg, 50 mg, or 100 mg once daily, mean
increases in SBP/DBP compared to placebo of approximately 0.5 – 1 mm Hg were observed.
Morning SBP increased by at least 15 mm Hg from baseline in 5.3%, 5.1%, and 6.7% of
placebo, MYRBETRIQ® 25 mg and MYRBETRIQ® 50 mg patients, respectively. Morning DBP
increased by at least 10 mm Hg in 4.6%, 4.1% and 6.6% of placebo, MYRBETRIQ® 25 mg, and
MYRBETRIQ® 50 mg patients, respectively. Both SBP and DBP increases were reversible upon
discontinuation of treatment.
Effect On Intraocular Pressure (IOP)
MYRBETRIQ® 100 mg once daily did not increase IOP in healthy subjects after 56 days of
treatment. In a phase 1 study assessing the effect of MYRBETRIQ® on IOP using Goldmann
applanation tonometry in 310 healthy subjects, a dose of MYRBETRIQ® 100 mg was non-
inferior to placebo for the primary endpoint of the treatment difference in mean change from
baseline to day 56 in subject-average IOP; upper bound of the two-sided 95% CI of the treatment
difference between MYRBETRIQ® 100 mg and placebo was 0.3 mm Hg.
Pharmacokinetics
Absorption
After oral administration of mirabegron in healthy volunteers, mirabegron is absorbed to reach

maximum plasma concentrations (Cmax) at approximately 3.5 hours. The absolute
bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax
and AUC increase more than dose proportionally. This relationship is more apparent at doses
above 50 mg. In the overall population of males and females, a 2-fold increase in dose from 50
mg to 100 mg mirabegron increased Cmax and AUCtau by approximately 2.9-and 2.6-fold,
respectively, whereas a 4-fold increase in dose from 50 to 200 mg mirabegron increased Cmax
and AUCtau by approximately 8.4-and 6.5-fold. Steady state concentrations are achieved within
7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure
of mirabegron at steady state is approximately double that seen after a single dose.
Effect Of Food
Co-administration of a 50 mg tablet with a high-fat meal reduced mirabegron Cmax and AUC by
45% and 17%, respectively. A low-fat meal decreased mirabegron Cmax and AUC by 75% and
51%, respectively. In the phase 3 studies, mirabegron was administered irrespective of food
contents and intake (i.e., with or without food) and demonstrated both safety and efficacy.
Therefore, mirabegron can be taken with or without food at the recommended dose [see
DOSAGE AND ADMINISTRATION].
Distribution
Mirabegron is extensively distributed in the body. The volume of distribution at steady state
(Vss) is approximately 1670 L following intravenous administration. Mirabegron is bound
(approximately 71%) to human plasma proteins, and shows moderate affinity for albumin and
alpha-1 acid glycoprotein. Mirabegron distributes to erythrocytes. Based on in vitro study
erythrocyte concentrations of 14C-mirabegron were about 2-fold higher than in plasma.
Metabolism
Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct)

glucuronidation, and amide hydrolysis. Mirabegron is the major circulating component following
a single dose of 14C-mirabegron. Two major metabolites were observed in human plasma and are
phase 2 glucuronides representing 16% and 11% of total exposure, respectively. These
metabolites are not pharmacologically active toward beta-3 adrenergic receptor. Although in
vitro studies suggest a role for CYP2D6 and CYP3A4 in the oxidative metabolism of
mirabegron, in vivo results indicate that these isozymes play a limited role in the overall
elimination. In healthy subjects who are genotypically poor metabolizers of CYP2D6, mean
Cmax and AUCtau were approximately 16% and 17% higher than in extensive metabolizers of
CYP2D6, respectively. In vitro and ex vivo studies have shown the involvement of
butylcholinesterase, uridine diphospho-glucuronosyltransferases (UGT) and possibly alcohol
dehydrogenase in the metabolism of mirabegron, in addition to CYP3A4 and CYP2D6.
Excretion
Total body clearance (CLtot) from plasma is approximately 57 L/h following intravenous
administration. The terminal elimination half-life (t1/2) is approximately 50 hours. Renal
clearance (CLR) is approximately 13 L/h, which corresponds to nearly 25% of CLtot. Renal
elimination of mirabegron is primarily through active tubular secretion along with glomerular
filtration. The urinary elimination of unchanged mirabegron is dose-dependent and ranges from
approximately 6.0% after a daily dose of 25 mg to 12.2% after a daily dose of 100 mg.
Following the administration of 160 mg 14C-mirabegron solution to healthy volunteers,
approximately 55% of the radioactivity dose was recovered in the urine and 34% in the feces.
Approximately 25% of unchanged mirabegron was recovered in urine and 0% in feces.

MYRBETRIQ

Uploaded by

Copyright:

Available Formats

MYRBETRIQ

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

MYRBETRIQ

Uploaded by

Copyright:

Available Formats

MYRBETRIQ® is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with

symptoms of urge urinary incontinence, urgency, and urinary frequency.

Adverse effects by incidence:[1][8][9]

Very common (>10% incidence) adverse effects include:

 Elevated blood pressure

Common (1–10% incidence) adverse effects include:

Rare (<1% incidence) adverse effects include:

Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR) as demonstrated by in

MYRBETRIQ® is contraindicated in patients who have known hypersensitivity reactions to

Effects On Blood Pressure

In another study in 96 healthy subjects to assess the impact of age on pharmacokinetics of

After oral administration of mirabegron in healthy volunteers, mirabegron is absorbed to reach

Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct)

You might also like